- Price
- $104.94
- Day
- +10.54%
- Mkt Cap
- $9.11B
- 52W Range
- $14.51 – $105.25
- Volume
- 818.4K
- Beta
- 3.03
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), demonstrating best-in-class efficacy potential and a safety profile consistent with in-class comparators
Read full article
Shares of Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eleven have issued a buy recommendation
Read full article
Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report)'s stock price rose 5.7% during trading on Friday. The stock traded as high as $99.41 and last traded at $99.45. 213,529 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 1,104,824 shares. The stock had previously closed at $94.12.
Read full article